Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2016

View Archived Issues

Primex Pharmaceuticals licenses oral solution for pediatric anesthesia from Advicenne

Boehringer Ingelheim and Hydra Biosciences disclose TrpC5 inhibitors

Merck & Co. patents free fatty acid receptor 1 agonists

Pharmacyclics introduces BTK inhibitors

First patient dosed in phase IIa study of factor VIIa-CTP for the treatment of hemophilia

4DMT and CRF partner to develop gene therapy treatment for choroideremia

Neutrophil elastase inhibitors described in Boehringer Ingelhiem patents

Vaginal ring containing dapivirine reduces the risk of HIV-1 infection among African women

Myriad and AbbVie expand strategic research collaboration

ViiV Healthcare completes acquisition of Bristol-Myers Squibb HIV R&D portfolio

Sanofi to return U.S. and Canadian rights for Auvi-Q to kaleo

Positive topline results from phase I trial of SOR-C13 in patients with advanced solid tumors

Novo Nordisk reports results from third phase IIIa trial of semaglutide in type 2 diabetes

FDA approves Ibrance for new metastatic breast cancer indication

Galunisertib plus lomustine not superior to monotherapies in phase II glioblastoma study

Promising phase II results for AdV-tk plus valacyclovir adjuvant to SOC in malignant glioma

OncBioMune reports phase I results for prostate cancer vaccine ProscaVax

FDA refuses to file PTC Therapeutics' NDA for ataluren

Novan initiates phase III program of SB-204 for acne

New study to explore utility of ambroxol for Parkinson's disease

First U.S. hospital-based rapid test for the Zika virus now available

ImmunID signs master collaboration agreement with MSK to validate ImmunTraCkeR utility

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...